Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Benjamin Hohl, CFO, on September 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $303
Helen Louise Collins, Chief Medical Officer, on September 17, 2026, sold 5,000 shares in Enliven The
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.